Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.

Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M.

Mol Cancer Res. 2019 Sep 19. doi: 10.1158/1541-7786.MCR-19-0264. [Epub ahead of print]

PMID:
31537618
2.

Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.

Li X, Valdes SA, Alzhrani RF, Hufnagel S, Hursting SD, Cui Z.

ACS Appl Mater Interfaces. 2019 Feb 20;11(7):7311-7319. doi: 10.1021/acsami.8b16588. Epub 2019 Feb 11.

PMID:
30689348
3.

The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth.

Bowers LW, Lineberger CG, Ford NA, Rossi EL, Punjala A, Camp KK, Kimler BK, Fabian CJ, Hursting SD.

Breast Cancer Res Treat. 2019 Feb;173(3):545-557. doi: 10.1007/s10549-018-5021-6. Epub 2018 Oct 26.

4.

Body Fatness, Adipose Tissue Compartments, and Biomarkers of Inflammation and Angiogenesis in Colorectal Cancer: The ColoCare Study.

Himbert C, Ose J, Nattenmüller J, Warby CA, Holowatyj AN, Böhm J, Lin T, Haffa M, Gigic B, Hardikar S, Scherer D, Zielske L, Schrotz-King P, Kölsch T, Siegel EM, Shibata D, Ulrich A, Schneider M, Hursting SD, Kauczor HU, Ulrich CM.

Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):76-82. doi: 10.1158/1055-9965.EPI-18-0654. Epub 2018 Oct 17.

PMID:
30333223
5.

Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms.

Ulrich CM, Himbert C, Holowatyj AN, Hursting SD.

Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):683-698. doi: 10.1038/s41575-018-0053-2. Review.

6.

Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.

Bowers LW, Rossi EL, McDonell SB, Doerstling SS, Khatib SA, Lineberger CG, Albright JE, Tang X, deGraffenried LA, Hursting SD.

Mol Cancer Res. 2018 May;16(5):869-879. doi: 10.1158/1541-7786.MCR-17-0508. Epub 2018 Feb 16.

7.

Research Strategies for Nutritional and Physical Activity Epidemiology and Cancer Prevention.

Mahabir S, Willett WC, Friedenreich CM, Lai GY, Boushey CJ, Matthews CE, Sinha R, Colditz GA, Rothwell JA, Reedy J, Patel AV, Leitzmann MF, Fraser GE, Ross S, Hursting SD, Abnet CC, Kushi LH, Taylor PR, Prentice RL.

Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):233-244. doi: 10.1158/1055-9965.EPI-17-0509. Epub 2017 Dec 18. Review.

8.

Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer.

Rossi EL, Khatib SA, Doerstling SS, Bowers LW, Pruski M, Ford NA, Glickman RD, Niu M, Yang P, Cui Z, DiGiovanni J, Hursting SD.

Mol Carcinog. 2018 Mar;57(3):393-407. doi: 10.1002/mc.22763. Epub 2017 Dec 1.

9.

Translating Mechanism-Based Strategies to Break the Obesity-Cancer Link: A Narrative Review.

Smith LA, O'Flanagan CH, Bowers LW, Allott EH, Hursting SD.

J Acad Nutr Diet. 2018 Apr;118(4):652-667. doi: 10.1016/j.jand.2017.08.112. Review.

10.

Obesity and Cancer Metabolism: A Perspective on Interacting Tumor-Intrinsic and Extrinsic Factors.

Doerstling SS, O'Flanagan CH, Hursting SD.

Front Oncol. 2017 Sep 14;7:216. doi: 10.3389/fonc.2017.00216. eCollection 2017. Review.

11.

Early Exposure to a High Fat/High Sugar Diet Increases the Mammary Stem Cell Compartment and Mammary Tumor Risk in Female Mice.

Lambertz IU, Luo L, Berton TR, Schwartz SL, Hursting SD, Conti CJ, Fuchs-Young R.

Cancer Prev Res (Phila). 2017 Oct;10(10):553-562. doi: 10.1158/1940-6207.CAPR-17-0131. Epub 2017 Sep 13.

12.

Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells.

Lyons A, Coleman M, Riis S, Favre C, O'Flanagan CH, Zhdanov AV, Papkovsky DB, Hursting SD, O'Connor R.

J Biol Chem. 2017 Oct 13;292(41):16983-16998. doi: 10.1074/jbc.M117.792838. Epub 2017 Aug 18.

13.

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer.

O'Flanagan CH, Rossi EL, McDonell SB, Chen X, Tsai YH, Parker JS, Usary J, Perou CM, Hursting SD.

NPJ Breast Cancer. 2017 Jul 17;3:26. doi: 10.1038/s41523-017-0027-5. eCollection 2017.

14.

When less may be more: calorie restriction and response to cancer therapy.

O'Flanagan CH, Smith LA, McDonell SB, Hursting SD.

BMC Med. 2017 May 24;15(1):106. doi: 10.1186/s12916-017-0873-x. Review.

15.

Energy Balance Modulation Impacts Epigenetic Reprogramming, ERα and ERβ Expression, and Mammary Tumor Development in MMTV-neu Transgenic Mice.

Rossi EL, Dunlap SM, Bowers LW, Khatib SA, Doerstling SS, Smith LA, Ford NA, Holley D, Brown PH, Estecio MR, Kusewitt DF, deGraffenried LA, Bultman SJ, Hursting SD.

Cancer Res. 2017 May 1;77(9):2500-2511. doi: 10.1158/0008-5472.CAN-16-2795. Epub 2017 Apr 3.

16.

Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model.

Allott EH, Macias E, Sanders S, Knudsen BS, Thomas GV, Hursting SD, Freedland SJ.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):165-171. doi: 10.1038/pcan.2016.73. Epub 2017 Feb 28.

17.

Energy balance and obesity: what are the main drivers?

Romieu I, Dossus L, Barquera S, Blottière HM, Franks PW, Gunter M, Hwalla N, Hursting SD, Leitzmann M, Margetts B, Nishida C, Potischman N, Seidell J, Stepien M, Wang Y, Westerterp K, Winichagoon P, Wiseman M, Willett WC; IARC working group on Energy Balance and Obesity.

Cancer Causes Control. 2017 Mar;28(3):247-258. doi: 10.1007/s10552-017-0869-z. Epub 2017 Feb 17.

18.

Metabolic Reprogramming by Folate Restriction Leads to a Less Aggressive Cancer Phenotype.

Ashkavand Z, O'Flanagan C, Hennig M, Du X, Hursting SD, Krupenko SA.

Mol Cancer Res. 2017 Feb;15(2):189-200. doi: 10.1158/1541-7786.MCR-16-0317.

19.

Starving cancer from the outside and inside: separate and combined effects of calorie restriction and autophagy inhibition on Ras-driven tumors.

Lashinger LM, O'Flanagan CH, Dunlap SM, Rasmussen AJ, Sweeney S, Guo JY, Lodi A, Tiziani S, White E, Hursting SD.

Cancer Metab. 2016 Sep 16;4:18. doi: 10.1186/s40170-016-0158-4. eCollection 2016.

20.

Reducing the burden of obesity-associated cancers with anti-inflammatory long-chain omega-3 polyunsaturated fatty acids.

Khatib SA, Rossi EL, Bowers LW, Hursting SD.

Prostaglandins Other Lipid Mediat. 2016 Sep;125:100-7. doi: 10.1016/j.prostaglandins.2016.07.011. Epub 2016 Jul 19. Review.

21.

Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer.

Devlin KL, Sanford T, Harrison LM, LeBourgeois P, Lashinger LM, Mambo E, Hursting SD.

PLoS One. 2016 Jul 19;11(7):e0159686. doi: 10.1371/journal.pone.0159686. eCollection 2016.

22.

Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.

Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z.

Mol Pharm. 2016 Jun 6;13(6):1833-42. doi: 10.1021/acs.molpharmaceut.5b00987. Epub 2016 Apr 26.

23.

Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.

McCampbell AS, Mittelstadt ML, Dere R, Kim S, Zhou L, Djordjevic B, Soliman PT, Zhang Q, Wei C, Hursting SD, Lu KH, Broaddus RR, Walker CL.

Curr Mol Med. 2016;16(3):252-65.

24.

Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice.

Rossi EL, de Angel RE, Bowers LW, Khatib SA, Smith LA, Van Buren E, Bhardwaj P, Giri D, Estecio MR, Troester MA, Hair BY, Kirk EL, Gong T, Shen J, Dannenberg AJ, Hursting SD.

Cancer Prev Res (Phila). 2016 May;9(5):339-48. doi: 10.1158/1940-6207.CAPR-15-0348. Epub 2016 Feb 11.

25.

Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.

Naguib YW, Lansakara-P D, Lashinger LM, Rodriguez BL, Valdes S, Niu M, Aldayel AM, Peng L, Hursting SD, Cui Z.

Neoplasia. 2016 Jan;18(1):33-48. doi: 10.1016/j.neo.2015.11.012.

26.

Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.

Bowers LW, Wiese M, Brenner AJ, Rossi EL, Tekmal RR, Hursting SD, deGraffenried LA.

PLoS One. 2015 Dec 28;10(12):e0145452. doi: 10.1371/journal.pone.0145452. eCollection 2015.

27.

Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.

Fabian CJ, Kimler BF, Phillips TA, Box JA, Kreutzjans AL, Carlson SE, Hidaka BH, Metheny T, Zalles CM, Mills GB, Powers KR, Sullivan DK, Petroff BK, Hensing WL, Fridley BL, Hursting SD.

Cancer Prev Res (Phila). 2015 Oct;8(10):912-21. doi: 10.1158/1940-6207.CAPR-14-0335.

28.

Obesity and cancer: mechanistic insights from transdisciplinary studies.

Allott EH, Hursting SD.

Endocr Relat Cancer. 2015 Dec;22(6):R365-86. doi: 10.1530/ERC-15-0400. Epub 2015 Sep 15. Review.

29.

Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.

Fabian CJ, Kimler BF, Phillips TA, Nydegger JL, Kreutzjans AL, Carlson SE, Hidaka BH, Metheny T, Zalles CM, Mills GB, Powers KR, Sullivan DK, Petroff BK, Hensing WL, Fridley BL, Hursting SD.

Cancer Prev Res (Phila). 2015 Oct;8(10):922-31. doi: 10.1158/1940-6207.CAPR-14-0336. Epub 2015 Aug 14.

30.

A weighty problem: metabolic perturbations and the obesity-cancer link.

O'Flanagan CH, Bowers LW, Hursting SD.

Horm Mol Biol Clin Investig. 2015 Aug;23(2):47-57. doi: 10.1515/hmbci-2015-0022. Review.

31.

Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.

Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, Kimler BF, Carlson SE, Shureiqi I, deGraffenried LA, Fabian CJ, Hursting SD.

Cancer Prev Res (Phila). 2015 Sep;8(9):796-806. doi: 10.1158/1940-6207.CAPR-15-0018. Epub 2015 Jun 22.

32.

The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.

Bowers LW, Rossi EL, O'Flanagan CH, deGraffenried LA, Hursting SD.

Front Endocrinol (Lausanne). 2015 May 15;6:77. doi: 10.3389/fendo.2015.00077. eCollection 2015. Review.

33.

Omega-3 fatty acids for breast cancer prevention and survivorship.

Fabian CJ, Kimler BF, Hursting SD.

Breast Cancer Res. 2015 May 4;17:62. doi: 10.1186/s13058-015-0571-6. Review.

34.

Risk profiles for weight gain among postmenopausal women: a classification and regression tree analysis approach.

Jung SY, Vitolins MZ, Fenton J, Frazier-Wood AC, Hursting SD, Chang S.

PLoS One. 2015 Mar 30;10(3):e0121430. doi: 10.1371/journal.pone.0121430. eCollection 2015.

35.

Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.

Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD.

Diabetes. 2015 May;64(5):1632-42. doi: 10.2337/db14-1132. Epub 2015 Jan 9.

36.

Obesity, Diabetes and Cancer: A Mechanistic Perspective.

Cifarelli V, Hursting SD.

Int J Diabetol Vasc Dis Res. 2015;2015(Suppl 4). doi: 10.19070/2328-353X-SI04001. Epub 2015 Sep 28.

37.

Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.

Bowers LW, Brenner AJ, Hursting SD, Tekmal RR, deGraffenried LA.

Breast Cancer Res Treat. 2015 Jan;149(1):49-57. doi: 10.1007/s10549-014-3223-0. Epub 2014 Dec 5.

38.

Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin.

Niu M, Naguib YW, Aldayel AM, Shi YC, Hursting SD, Hersh MA, Cui Z.

Mol Pharm. 2014 Dec 1;11(12):4425-36. doi: 10.1021/mp500565q. Epub 2014 Oct 27.

39.

Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers.

Paxton RJ, Jung SY, Vitolins MZ, Fenton J, Paskett E, Pollak M, Hays-Grudo J, Hursting SD, Chang S.

Cancer Causes Control. 2014 Nov;25(11):1427-37. doi: 10.1007/s10552-014-0434-y. Epub 2014 Sep 20.

40.

NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, Tekmal RR, Jolly CA, deGraffenried LA.

Cancer Res. 2014 Aug 15;74(16):4446-57. doi: 10.1158/0008-5472.CAN-13-3603.

41.

Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation.

Lashinger LM, Rossi EL, Hursting SD.

Clin Pharmacol Ther. 2014 Oct;96(4):458-63. doi: 10.1038/clpt.2014.136. Epub 2014 Jun 24. Review.

PMID:
24960521
42.

Calorie restriction decreases murine and human pancreatic tumor cell growth, nuclear factor-κB activation, and inflammation-related gene expression in an insulin-like growth factor-1-dependent manner.

Harvey AE, Lashinger LM, Hays D, Harrison LM, Lewis K, Fischer SM, Hursting SD.

PLoS One. 2014 May 7;9(5):e94151. doi: 10.1371/journal.pone.0094151. eCollection 2014.

43.

Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression.

Olivo-Marston SE, Hursting SD, Perkins SN, Schetter A, Khan M, Croce C, Harris CC, Lavigne J.

PLoS One. 2014 Apr 14;9(4):e94765. doi: 10.1371/journal.pone.0094765. eCollection 2014.

44.

Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice.

Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD.

Cancer Metab. 2014 Mar 31;2(1):6. doi: 10.1186/2049-3002-2-6.

45.

Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation.

Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO 3rd, Cui Z.

Mol Pharm. 2014 Apr 7;11(4):1239-49. doi: 10.1021/mp4006968. Epub 2014 Mar 12.

46.

Bioavailable insulin-like growth factor-I inversely related to weight gain in postmenopausal women regardless of exogenous estrogen.

Jung SY, Hursting SD, Guindani M, Vitolins MZ, Paskett E, Chang S.

Cancer Epidemiol Biomarkers Prev. 2014 Mar;23(3):534-44. doi: 10.1158/1055-9965.EPI-13-1053. Epub 2013 Dec 20.

47.

Interacting inflammatory and growth factor signals underlie the obesity-cancer link.

Lashinger LM, Ford NA, Hursting SD.

J Nutr. 2014 Feb;144(2):109-13. doi: 10.3945/jn.113.178533. Epub 2013 Nov 27. Review.

48.

Calorie restriction and cancer prevention: a mechanistic perspective.

Hursting SD, Dunlap SM, Ford NA, Hursting MJ, Lashinger LM.

Cancer Metab. 2013 Mar 7;1(1):10. doi: 10.1186/2049-3002-1-10.

49.

Metformin inhibits skin tumor promotion in overweight and obese mice.

Checkley LA, Rho O, Angel JM, Cho J, Blando J, Beltran L, Hursting SD, DiGiovanni J.

Cancer Prev Res (Phila). 2014 Jan;7(1):54-64. doi: 10.1158/1940-6207.CAPR-13-0110. Epub 2013 Nov 6.

50.

Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women.

Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, Aversman S, Yeh HW, Zalles CM, Mills GB, Hursting SD.

Breast Cancer Res Treat. 2013 Nov;142(1):119-32. doi: 10.1007/s10549-013-2730-8. Epub 2013 Oct 19.

Supplemental Content

Loading ...
Support Center